Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
47.14
-1.56 (-3.20%)
At close: Apr 28, 2026, 4:00 PM EDT
47.16
+0.02 (0.04%)
Pre-market: Apr 29, 2026, 6:00 AM EDT
Moderna Revenue
In the year 2025, Moderna had annual revenue of $1.94B, down -39.93%. Moderna had revenue of $678.00M in the quarter ending December 31, 2025, a decrease of -29.81%.
Revenue (ttm)
$1.94B
Revenue Growth
-39.93%
P/S Ratio
9.62
Revenue / Employee
$413,617
Employees
4,700
Market Cap
18.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | -1.29B | -39.93% |
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Ascendis Pharma | 845.52M |
| Insmed | 606.42M |
| BridgeBio Pharma | 502.08M |
MRNA News
- 4 days ago - CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
- 7 days ago - Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
- 7 days ago - Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Accesswire
- 7 days ago - Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - Accesswire
- 7 days ago - Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
- 7 days ago - Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - Accesswire
- 7 days ago - Moderna to Present at Upcoming Conferences in May 2026 - Accesswire
- 11 days ago - Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting - Accesswire